The National Standards for Colorectal Cancer Screening & Diagnosis

Objectives

The National Colorectal Cancer Screening Programme in the United Arab Emirates establishes minimum requirements for safe, evidence-based colorectal cancer screening, assessment, follow-up and referral across Ministry of Health-licensed providers, including mobile units. It defines the eligible population, service case mix, clinical standards, screening intervals and data-reporting expectations, aiming to identify colorectal cancer and precancerous lesions early and ensure timely diagnostic assessment or treatment.[1][2]

• Provide screening to average-risk men and women aged 40 to 75 years who meet the eligibility criteria.[2]
• Offer screening colonoscopy every 10 years as the preferred option, and offer a faecal immunochemical test every two years where an eligible person declines colonoscopy.[3]
• Apply risk-based pathways that distinguish average-, increased- and high-risk individuals, including those with personal or family histories of adenomas, colorectal cancer, inflammatory bowel disease or hereditary polyposis syndromes.[4][5]
• Detect suspected lesions through colonoscopy, which enables visual examination, biopsy and lesion removal, and use faecal immunochemical testing as a non-invasive screening modality.[2]
• Recruit eligible people through targeted invitations that support identification, participation and retention, while also using opportunistic recruitment during clinical consultations and health-promotion campaigns.[6]
• Ensure prompt follow-up after abnormal screening findings, including urgent referral for colonoscopy after a positive faecal immunochemical test and specialist assessment at an oncology centre for patients requiring urgent review.[7][8]
• Support definitive management after screening-detected cancer through referral pathways and performance expectations for the interval between a positive colonoscopy and the start of treatment.[7][4]
• Standardise collection of demographic, risk-history, screening, test-result, referral and outcome information through the screening registry, enabling consistent documentation of screening pathways and recommended next steps.[9]

Implementation

Implementation relies on licensed healthcare facilities, laboratories, endoscopy units and trained multidisciplinary screening teams operating under clinical, information-governance and quality-assurance requirements. Providers are responsible for recruitment, risk assessment, consent, screening delivery, result communication, referral coordination, record-keeping, registry submission, internal audit and cooperation with Ministry of Health oversight.[2][10]

• Deliver screening, assessment and follow-up through licensed providers and facilities, with a designated colorectal cancer programme coordinator responsible for data submission and internal monitoring, evaluation and audits.[2][10]
• Establish referral protocols with diagnostic and oncology centres, coordinate referrals for people with positive results, and use multidisciplinary team review when assessing outcomes and planning onward care.[10][3]
• Maintain endoscopy-unit infrastructure for pre-procedure assessment, recovery, patient flow, capacity planning, video-endoscopy, intervention accessories and maintained resuscitation equipment.[4]
• Staff screening teams with at least two gastroenterologists and two trained nurses; require gastroenterologists to meet annual colonoscopy-volume expectations and participate in multidisciplinary meetings, while nurses provide patient support and screening information.[4]
• Undertake documented pre-colonoscopy assessment, risk classification, bowel preparation, infection-control and sedation procedures; seek and document informed consent; and explain procedures, risks and expected timelines to participants.[3][6]
• Perform and document colonoscopy according to procedural standards, including examination completeness where possible, caecal identification, rectal retroflexion, withdrawal time, photographic evidence, findings, lesion location, polyp size, removal and retrieval methods, complications and follow-up plans.[6][11][7][12]
• Contact patients 24 hours after colonoscopy or on the next working day, provide discharge instructions and a contact number, and track complications for 30 days; report serious adverse events under applicable adverse-event management standards.[11]
• Offer faecal immunochemical testing to people declining colonoscopy, give clear sample-collection instructions, assure sample identification, quality, preservation and timely analysis, and repeat testing where a result is unclear or a sample is spoiled.[7]
• Require laboratories to maintain compliant systems and procedures for specimen identification, labelling, diagnostic histopathology and genetic testing, with relevant specialist support, regular audit and Ministry-recognised international accreditation within 18 months of issuance of the standard.[10][3]
• Communicate written screening results, follow-up instructions, treatment referrals or future screening dates to participants, and provide feedback to the referring physician or primary ambulatory healthcare clinic.[7]
• Submit screening-visit and outcome data to the National Cancer Screening Registry at the Ministry of Health, and report confirmed screening-detected cancers to the National Cancer Registry.[2]
• Monitor service quality against defined standards, including screening uptake, colonoscopy volume, inadequate faecal immunochemical test samples, result turnaround, follow-up after positive tests, caecal intubation, adenoma detection, withdrawal time, polyp retrieval, complications and time to definitive management.[8]
• Meet specified key thresholds, including results within 15 working days for more than 90% of participants, inadequate faecal immunochemical test samples below 3%, bowel preparation inadequacy not exceeding 10%, and withdrawal time of at least six minutes where neither biopsy nor polypectomy is undertaken.[6][7][8]
• Protect patient information, comply with information-technology and medical-record requirements, permit authorised record inspection and auditing, and cooperate with Ministry oversight; healthcare providers, payers and third-party administrators are subject to sanctions for non-compliance.[2][10]

Monitoring & Evaluation

Monitoring and accountability are centred on mandatory data capture, clinical quality standards, registry reporting, internal audit, laboratory quality assurance, and oversight by the Ministry of Health. Providers must submit screening-visit and outcome data to the National Cancer Screening Registry, while confirmed screening-detected cancers must be notified to the National Cancer Registry.[2]

• Maintain screening and outcome records, appoint a colorectal cancer programme coordinator, and undertake internal audits, monitoring and evaluation within each provider organisation.[10]
• Submit data on patient demographics, risk history, recruitment route, prior screening, colonoscopy findings, faecal immunochemical test results, notifications, referrals, and recommended next actions through the screening registry.[9]
• Monitor compliance with clinical performance indicators and timelines, although the supplied material does not provide a complete indicator specification or reporting timetable beyond the appendices.[2][10]
• Enable authorised inspections and audits by maintaining compliant medical records and cooperating with Ministry of Health oversight arrangements.[2][10]
• Obtain laboratory accreditation from an internationally credible body recognised by the Ministry of Health within 18 months of issuance of the standard, and participate in regular laboratory audits, monitoring and evaluation.[3]
• Permit independent third-party quality-assurance testing of laboratories delivering colorectal cancer screening services.[3]
• Document colonoscopy risk assessment, informed consent, preparation, procedure completion, photographic evidence, findings, adverse events, discharge arrangements, and follow-up in patient records suitable for audit.[6][11][12]
• Record serious adverse clinical events in accordance with adverse-event management standards, contact patients 24 hours after colonoscopy or on the next working day, and track complications for 30 days.[11]
• Monitor unacceptable faecal immunochemical test samples, with a maximum rate of 3% and a desirable rate below 1%.[7]
• Provide written screening results, follow-up instructions, treatment referrals or future screening dates to participants, and communicate feedback to the referring physician or primary ambulatory healthcare clinic.[7]
• Ensure screening results reach participants within 15 working days for more than 90% of cases.[7]
• Urgently refer people with positive faecal immunochemical test results for follow-up colonoscopy within 15 working days, and repeat testing where results are unclear or samples are spoiled.[7]
• Audit adenoma detection rates, track the interval from a cancer-indicating positive colonoscopy to definitive management, and electronically notify deaths attributed to colonoscopy complications within 30 days.[7]

The performance framework sets acceptable and desirable thresholds across access, test quality, endoscopy quality, complications, referral timeliness and treatment initiation. Screening uptake above 45% is acceptable and above 65% desirable; annual screening colonoscopy volume above 150 per colonoscopist is acceptable and above 300 desirable.[8]More than 90% of positive faecal immunochemical test cases should be referred for colonoscopy, with more than 95% desirable; more than 90% of follow-up colonoscopies should occur within 31 days, with more than 95% desirable.[8]

• Maintain a caecal intubation rate above 90% as acceptable and above 95% as desirable.[8]
• Achieve an adenoma detection rate of at least 35%, a withdrawal time of at least six minutes in negative colonoscopies, and polyp retrieval above 90% as acceptable and above 95% as desirable.[8]
• Keep inadequate bowel preparation below 10% of examinations and document withdrawal times where no biopsy or polypectomy is undertaken.[6]
• Limit colonoscopy-programme bleeding complications to below 1 in 150, perforation to 1 in 1,000, and post-polypectomy perforation to below 1 in 500.[8]
• Ensure more than 90% of patients commence definitive management within 31 days after a positive colonoscopy, with more than 95% as the desirable standard.[8]
• Assess colonoscopist performance through annual procedure volume and caecal completion rates exceeding 90%, and review colonoscope functioning and cleansing regularly.[4]

Costing & Financing

The supplied material does not specify a programme budget, unit costs, overall funding requirement, funding gap, resource-mobilisation plan, economic assumptions, or dedicated financing source for colorectal cancer screening.[3][6][11][7][4][5][12]Reimbursement eligibility is instead linked to compliance with the applicable health-insurance laws in each Emirate.[2]

• Require providers and laboratories to maintain infrastructure, equipment, personnel, records, quality-assurance systems and accreditation arrangements, but provide no associated costings or funding allocations.[10][3][4]
• Apply reimbursement eligibility under local Emirate health-insurance legislation; the supplied text does not specify reimbursement rates, payer contributions, benefit limits or financing responsibilities.[2]
• Leave unspecified the financial implications of registry reporting, laboratory accreditation, third-party quality assurance, follow-up colonoscopy, oncology referral, definitive management, adverse-event monitoring and screening outreach.[2][3][6][11][8]